Jump to contentJump to search
Symbolbild Neurone im Raum
Foto von

Group leader: Translational Neurotechnologies

Univ.-Prof. Dr. rer. nat. Ulf D. Kahlert
Neurosurgical Clinic
Moorenstraße 5
40225 Düsseldorf

Research Interest

In my research at the Department of Neurosurgery I aim to identify molecular paradigms with suitability for rapid application in clinical neuro-oncology.

The central paradigm of my work is to understand the biology of stem-like cells and epithelial to mesenchymal transition (EMT) in brain tumors – responsible for the development, progression and therapy resistant of the diseases. I my work I use a variety of stem cell assays and draw particular caution on the phylogenetically conserved stem cell signaling cascades Notch and Wingless (WNT). We also develop stem cell-based models for cancers using human induced pluripotent stem cells (hiPSC).

Experimental approaches are initiated and results will be validated for clinical relevance with in depth genetic and epigenetic characterization of brain tumors from patients in our clinic as well as external clinical datasets. Moreover I am interested in the use of stem cells for neuro regeneration and to model pain.

Further information
Most important publications
  1. Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses. A C Nickel, D Picard, N Qin, M Wolter, K Kaulich, M Hewera, D Pauck, V Marquardt, G Torga, S Muhammad, W Zhang, O Schnell, H-J Steiger, D Hänggi, E Fritsche, N-G Her, D-H Nam, M S Carro, M Remke, G Reifenberger, U D Kahlert. Biomed Pharmacother. 2021 Dec;144:112278. doi: 10.1016/j.biopha.2021.112278. Epub 2021 Oct 7. PubMed
  2. Testing the Stability of Drug Resistance on Cryopreserved, Gene-Engineered Human Induced Pluripotent Stem Cells. Dilaware Khan, Ann-Christin Nickel, Sebastian Jeising, Constanze Uhlmann, Sajjad Muhammad, Daniel Hänggi, Igor Fischer, Ulf Dietrich Kahlert. Pharmaceuticals (Basel). 2021 Sep 11;14(9):919. doi: 10.3390/ph14090919. PubMed
  3. BCOR Internal Tandem Duplication Expression in Neural Stem Cells Promotes Growth, Invasion, and Expression of PRC2 Targets.
    Satoshi Nakata,Ming Yuan, Jeffrey A. Rubens, Ulf D. Kahlert, Jarek Maciaczyk, Eric H. Raabe, Charles G. Eberhart. Int. J. Mol. Sci. 2021, 22(8), 3913; doi.org/10.3390/ijms22083913 MDPI
  4. Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells.
    Li G, Chen TW, Nickel AC, Muhammad S, Steiger HJ, Tzaridis T, Hänggi D, Zeidler R, Zhang W, Kahlert UD. Onco Targets Ther. 2021 Mar 4;14:1707-1718. doi: 10.2147/OTT.S300623. eCollection 2021. PubMed
  5. Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide.
    Vargas-Toscano A, Nickel AC, Li G, Kamp MA, Muhammad S, Leprivier G, Fritsche E, Barker RA, Sabel M, Steiger HJ, Zhang W, Hänggi D, Kahlert UD. Cancers (Basel). 2020 Dec 21;12(12):3859. doi: 10.3390/cancers12123859. PubMed
  6. Different Calculation Strategies Are Congruent in Determining Chemotherapy Resistance of Brain Tumors In Vitro.
    Fischer I, Nickel AC, Qin N, Taban K, Pauck D, Steiger HJ, Kamp M, Muhammad S, Hänggi D, Fritsche E, Remke M, Kahlert UD.Cells. 2020 Dec 15;9(12):2689. doi: 10.3390/cells9122689. PubMed
  7. A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma.
    Herrera-Rios D, Li G, Khan D, Tsiampali J, Nickel AC, Aretz P, Hewera M, Suwala AK, Jiang T, Steiger HJ, Kamp MA, Muhammad S, Hänggi D, Maciaczyk J, Zhang W, Kahlert UD. Sci Rep. 2020 Oct 1;10(1):16218. doi: 10.1038/s41598-020-72480-y. PubMed
  8. An inexpensive and easy-to-implement approach to a Quality Management System for an academic research lab.
    Hewera M, Nickel AC, Knipprath N, Muhammad S, Fan X, Steiger HJ, Hänggi D, Kahlert UD. F1000Res. 2020 Jun 30;9:660. doi: 10.12688/f1000research.24494.2. eCollection 2020. PubMed
  9. Robot technology identifies a Parkinsonian therapeutics repurpose to target stem cells of glioblastoma.
    Vargas-Toscano A, Khan D, Nickel AC, Hewera M, Kamp MA, Fischer I, Steiger HJ, Zhang W, Muhammad S, Hänggi D, Kahlert UD. CNS Oncol. 2020 Jun;9(2):CNS58. doi: 10.2217/cns-2020-0004. Epub 2020 May 28. PubMed
  10. A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity.
    Koch K, Hartmann R, Tsiampali J, Uhlmann C, Nickel AC, He X, Kamp MA, Sabel M, Barker RA, Steiger HJ, Hänggi D, Willbold D, Maciaczyk J, Kahlert UD. Cell Death Discov. 2020 Apr 16;6:20. doi: 10.1038/s41420-020-0258-3. eCollection 2020. PubMed
Responsible for the content: